Antares Pharma Inc. ($ATRS) stock is trading 0.5% in its current trading session. It also gained 33% in the past one month. The stock has shown consistent upward movement this year.
Antares Pharma Inc. stock is likely to benefit from its strong pipeline. The company recently reported the completion of its QuickShot® testosterone (QST) clinical program. It also provided the results of the dose-blinded, multiple-dose, concentration-controlled, 26-week phase 3 QST-15-005 study. Antares reported that it is on track for submitted the New Drug Application by December 31, 2016.
The company’s abstracts related to QuickShot were also accepted for presentation at the 22nd annual fall meeting of the Sexual Medicine Society of North America (SMSNA)
However, the company reported higher net loss for its third quarter at $6.1 million, in comparison to $5.7 million loss it had suffered in the comparable quarter of the previous year. However, it improved its quarterly revenue from $11.1 million to $13.5 million.
Antares Pharma Inc. is looking to redesign its organizational structure as it announced the appointment of Fred M. Powell as its new Chief Financial Officer and Senior Vice President. His 20 years long experience in corporate finance is likely to help the company in boosting its financial standing.